Get the Stockscreener App
15.27
19.48%
2.49
After Hours:
10.36
-4.91
-32.15%
Bioaffinity Technologies Inc stock is traded at $15.27, with a volume of 19.37M.
It is up +19.48% in the last 24 hours and up +2,674% over the past month.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
See More
Previous Close:
$12.78
Open:
$11.12
24h Volume:
19.37M
Relative Volume:
6.33
Market Cap:
$123.71M
Revenue:
$5.66M
Net Income/Loss:
$-15.88M
P/E Ratio:
-1.3497
EPS:
-11.3134
Net Cash Flow:
$-10.93M
1W Performance:
+213.55%
1M Performance:
+2,674%
6M Performance:
+1,383%
1Y Performance:
+112.79%
1-Day Range:
$10.90
$20.35
1-Week Range:
$4.56
$20.35
52-Week Range:
$0.3252
$20.35
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
15.27 | 3.24M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Price to earnings forward of bioAffinity Technologies, Inc. – BOATS:BIAFW - TradingView
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 - BioSpace
bioAffinity Technologies Implements Reverse Stock Split for Nasdaq - TipRanks
bioAffinity Technologies Sets 1-for-15 Reverse Stock Split for August 24 - citybiz
bioAffinity Technologies executes 1-for-15 reverse stock split - Investing.com
BioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 - marketscreener.com
bioAffinity (BIAF) Earnings Snapshot: The Available Earnings Metric Delivers a Miss in the Reported Period; Trading Move: The Stock Ends Down 13.59% in Latest TradingFinancial Summary - vinanet.vn
These stocks are the most active in today's session - ChartMill
bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung - Yahoo Finance
bioAffinity partners with AvMEDICAL for VA distribution - Investing.com
Form 8K bioAffinity Technologies Inc For: 18 August By Investing.com - Investing.com Nigeria
bioAffinity Technologies expands CyPath Lung federal distribution - TipRanks
bioAffinity Technologies inks federal distribution deal with AvMEDICAL to expand CyPath Lung access - TradingView
bioAffinity partners with AvMEDICAL for VA distribution By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
BioAffinity Technologies Closes $4 Million Private Placement - Moomoo
bioAffinity Technologies Warrant (BIAFW) Holds Steady at $0.06 as Trading Range ConvergesInsider Selling Alerts - vinanet.vn
bioAffinity Technologies closes $4M private placement - Investing.com
bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47 - Bitget
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire
bioAffinity Technologies closes $4M private placement By Investing.com - Investing.com Australia
BioAffinity Technologies Announces Closing of - Moomoo
BioAffinity Technologies, Inc. announced that it has received $3.940766 million in funding - marketscreener.com
bioAffinity Technologies prices $4M private placement offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies prices $4M private placement offering - Investing.com
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Barchart.com
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
BioAffinity Technologies, Inc. announced that it expects to receive $3.940766 million in funding - marketscreener.com
bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP - Medical Product Outsourcing
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com - Investing.com Nigeria
bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates - Investing.com Canada
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingView
BIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingView
Price to sales forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingView
bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingView
Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - Moomoo
bioAffinity Technologies Inc (BIAF) Stock News Today - TradingKey
BIAF Q3 2025 Earnings: Loss of $4.74 Per Share Misses Estimates by 72%Estimate Dispersion - vinanet.vn
bioAffinity Technologies (BIAF) Holds Steady at $0.53 as Shares Consolidate Between Key Support and ResistanceMomentum Trade - vinanet.vn
bioAffinity Technologies (BIAF) Slips 6.24% to $0.56 as Selling Pressure IntensifiesVolume Breadth - vinanet.vn
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
bioAffinity Technologies, Inc. Revenue Breakdown – NASDAQ:BIAF - TradingView
Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):